Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Executive Summary
Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication